N onadherence to medical therapy is frequently encountered in patients with inflammatory bowel diseases (IBDs). Identification of patients at risk for nonadherence and a timely intervention aimed at improving adherence might prevent an unfavorable disease course associated with this behavior. 1, 2 The mechanisms leading to nonadherence are presently incompletely understood. In previous studies, several sociodemographic factors such as lower age, sex, current employment, and single status have been found to be associated with nonadherence. [3] [4] [5] [6] [7] However, the prognostic value of previously identified factors, based on multivariable prediction modeling, has not yet been assessed. Also, it is unknown whether nonadherence at one time point predicts future nonadherence in the same individual.
According to the Common Sense Model, 8 illness perceptions about IBD play a major role in the adjustment to this chronic illness, and may weaken the impact of clinical characteristics on clinical outcomes. However, the association between illness perceptions and adherence behavior has only been studied for antitumor necrosis factor users. 9 The primary aim of this study was to identify easy-to-obtain clinical predictors for future nonadherence among patients with IBD. Secondary, we aimed to identify illness perceptions that accompany nonadherent behavior.
MATERIAL AND METHODS

Patient Population and Study Design
The COIN-study (Costs of inflammatory bowel disease in the Netherlands) is a large multicentre cohort study initiated in 2010 aimed at prospectively assessing the IBD-related health care costs, patient costs and productivity losses, and health-related quality of life (HrQoL). 10 All patients from 7 university medical centers and 7 general hospitals aged 18 years or older were eligible for participation, regardless of their current disease duration. The study design has previously been described in detail. 10 
Data Collection
Patients were invited to fill out a web-based baseline questionnaire, followed by three monthly questionnaires each with questions on HrQoL, disease activity scores, health care resources used, sick leave days, disease course items, medication used, and medication adherence. Demographic and general characteristics (sex, age, age at diagnosis, and IBD diagnosis) were included in the first questionnaire only.
Nonadherence to IBD-specific Medication
Adherence to IBD-specific medication was self-assessed during each follow-up moment, and only applicable for this study if patients used IBD-specific medication. A visual analogue scale ("VAS"), answering the question how well patients overall were taking their IBD medication on a scale ranging from 0% to 100% was used. Hundred percent indicated a perfect adherence and 0% indicated very bad adherence. Medication adherence rates (VAS) ,80% were considered nonadherent, and rates $80% were considered adherent. 11, 12 Distributions of medication adherence of study participants were presented with medians and interquartile ranges, and presented per person years. Adherence rates were presented per individual type of medication, per type of medication administration (i.e., oral, parenteral, intramuscular, and rectal), and per number of different types of IBD medication per patient.
Outcome: Future Nonadherence
The main outcome: "future" nonadherence was defined as being nonadherent in a 3 months' time span after the assessment of candidate predictors. For example, a disease flare at T ¼ 6 months of follow-up was incorporated as a predictor for (non) adherence at T ¼ 9 months of follow-up. Predictors at the first measurement in time were used to predict adherence at the second measurement in time, predictors at the second measurement in time were used to predict adherence at the third measurement in time and so forth. Therefore, nonadherence was analyzed prospectively.
Candidate Predictors
Based on previous studies [3] [4] [5] [6] [7] 13 and clinical reasoning, we selected candidate predictors for future nonadherence that would be easy to obtain by a physician in the setting of the outpatient clinic.
Patient Characteristics
Sex, current employment, age at diagnosis, currently living apart versus together in any form of relational partnership, smoking status (current, ex-smoker, or never-smoker), high or low education level were assessed at baseline (high education meaning education beyond high school).
Disease-related Factors
Type of IBD (Crohn's disease [CD] or ulcerative colitis [UC]), disease duration, current self-reported flares, the short Crohn's disease Activity Index (CDAI) 14 for patients with CD and the Modified Truelove and Witts Index (MTWSI) 15 for patients with UC, and (peri)anal fistulas (for patients with CD) were assessed at every 3-month time point.
Quality of Life Items
The separate 5 domains (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) of the EQ-5D-3L instrument 16 were assessed at every 3-month time point for 3 functioning levels (no problems, some problems, or severe problems). Answers were categorized into "no problems" or "any problems" (consisting of some problems or severe problems) regarding these 5 items. Health states were not analyzed in this study.
Sick Leave due to IBD-related Illness
Patients were asked during follow-up whether they had been called in sick from both paid and unpaid (voluntary) work due to IBD-related illness during the past 3 months.
Nonadherence
Nonadherence was also included as a candidate predictor for nonadherent behavior after 3 months. This means that, for example, an adherence measurement at T ¼ 6 months of followup was incorporated as predictor of (non)adherence 3 months later, at T ¼ 9 months of follow-up (and so forth).
Illness Perceptions and Adherence Behavior
Once during follow-up (at 27 months after the start of the COIN-study), the Brief Illness Perception Questionnaire (B-IPQ) was assessed. 17, 18 This nine-item questionnaire explores the cognitive and emotional representation of illness. The cognitive representation consists of identity, consequences, causes, timeline, and cure or control. The emotional representation incorporates negative reactions such as fear, anger, and distress. Items were assessed on a 10-point Likert scale, for example "How much does your illness affect your life?" 0 ("not at all")-10 ("severely affects my life"). Mean scores were compared between adherent and nonadherent patients, and logistic regression analysis was performed to study the association between individual items and nonadherence at the same moment.
Statistical Analysis
We used logistic regression analysis to estimate the association between the candidate predictors (measured at each time point) and the adherence outcome measured 3 months later. A residual (i.e., generalized estimating equation type) covariance matrix was included in the analyses to correct for repeated measurements within patients. 19 Time was included by allowing disease duration to increase with the follow-up. We evaluated all candidate predictors in a multivariable ("full") model, regardless of univariable statistical significance. Independent predictors were subsequently selected using backward selection. Type of IBD, sex, and age at diagnosis were always retained in the final selection, regardless of statistical significance. The final selection was based on Akaike's Information Criterion, which corresponds to a P value of 0.157 for a predictor with a single degree of freedom (i.e., one regression coefficient in the model). This criterion was chosen, as the "standard" P value for statistical significance of 0.05 may be too stringent for the evaluation of predictors. 20 The model's ability to discriminate between adherent and nonadherent patients was estimated with the c-statistic, which is similar to the area under the receiver-operatingcharacteristic curve for dichotomous outcomes at a single time point. This measure was not corrected for repeated measures to obtain a discriminative ability that fully incorporates differences in nonadherence both within and between patients at different time points (hence, it will be reported without potentially biased confidence intervals [CIs] ). In addition, the model was calibrated to evaluate its performance in both patients with CD and patients with UC separately (Appendix 1 for details). To retain full statistical power, we used multiple imputation techniques to account for missing data. 21 Data were imputed 5 times; all statistical analyses were subsequently performed on the 5 imputations separately. Missing values were imputed by a combination of health status variables, treatment variables, disease activity, and psychological measurements (disease-related HrQoL and general HrQoL) including the outcomes and all predictors (full details available on request). The results of the analyses were pooled using Rubin's rule. 22 The analyses of the association between illness perceptions and medication adherence were crosssectionally performed because this questionnaire was assessed only once. Medication use was reported per person-years (i.e., the total number of medication prescriptions divided by time; time meaning the multiplication of the number of patients with the number of 3 monthly time period in which the medication was used). Answers to the Brief Illness Perceptions Questionnaire were not imputed. Multiple imputation techniques and the analyses of adherence distributions were performed with SPSS version 21.0 (Armonk, NY: IBM Corp); prediction modeling was performed with SAS version 9.2, Cary, NC.
Ethical Considerations
This study was performed with the approval of the Medical Ethics Committee (MEC) of the University Medical Center Utrecht.
RESULTS
Patient Population
In total, 2612 patients (1588 CD and 1054 UC) participated in this study (Table 1) . Patients were followed for a maximum of 2.5 years. The response rate after 2 years was 47% for patients with CD and 54% for patients with UC. 23 An overview of total responders and missings per time point is shown in Appendix 1. A nonresponder analysis revealed that responders were older and had a longer disease duration as compared with nonresponders (patients who were lost to follow-up). Adherence scores of the responding study population after 2.5 years were not different compared with the total study population at the start of the study. Mean adherence scores at the first time point were higher in patients who remained in study throughout the full follow-up period (responders) compared with patients who were 
Distribution of Medication Adherence
At 3 months of follow-up after inclusion, 75.9% of patients used medication for IBD. Reported median adherence scores were high at 3 months, and did not differ between patients with CD and patients with UC (VAS 95.4% [interquartile range: 88.3-100] for patients with CD and 95.2% [interquartile range: 87.5-100]) for patients with UC (Table 1) .
In patients with CD, nonadherence was most frequently observed in patients using mesalazine (Table 2 ), in patients using rectally administrated medications, in patients with 3 administrations of medication per day, and in patients on monotherapy as compared with patients using 2 or 3 different kinds of IBD medication. In patients with UC, nonadherence was most frequently seen in patients using budesonide, rectally administrated medication, in patients with 5 or more administrations of medication per day, or in patients on monotherapy (Table 3) .
Medication Adherence During Follow-up
During each cycle of follow-up, most adherent patients with CD and patients with UC remained adherent within the 3 subsequent months after each measurement (91.1% and 92.2%, respectively). Of patients who were nonadherent at a single time point, most patients with CD and UC switched to adherent behavior within the 3 subsequent months (61.5% and 61.1%, respectively) (Fig. 1) .
Prediction of Future Nonadherence
Younger age at diagnosis, current flare, self-reported anxious or depressed feelings (EQ-5D-3L), and current nonadherence were independent predictors for future nonadherence in IBD (unadjusted associations: Table 4 ; final prediction model: Table 5 ). Among these factors, nonadherence was the highest contributing predictor with an adjusted odds ratio of 26.91 (95% CI, 22.67-31.94). The receiver-operating-characteristic area of the final model was 0.74. Calibration slopes for patients with CD and UC showed values of 0.96 (95% CI, 0.89-1.03) and 1.05 (95% CI, 0.96-1.14), respectively (Appendix 2 for details).
Illness Perceptions
In patients with CD, a better control over the disease and a higher level of perceived help of treatment were associated with a lower risk of nonadherent behavior (Table 6 ). In patients with UC, longer perceived disease duration (indicating that patients think their illness will continue longer), better control over the disease, higher level of understanding of the disease, and higher influence of the disease on the mood of patients were associated with a lower risk of nonadherent behavior.
DISCUSSION
In this large prospective cohort study, we identified lower age at diagnosis, current flares, self-reported anxious or depressed feelings, and current nonadherence as independent predictors for future nonadherence to medical therapy in IBD. Our final prediction model for future nonadherence performed reasonably well for the total IBD population, and for the CD or UC group separately. 24 Adherence to medical therapy was found to be associated with higher perceived treatment control and comprehension of the disease.
Our results confirm that lower age is a predictor of nonadherence. 3, 25 Gender was not found to predict nonadherence. Both female and male sex have been identified as a predictor of nonadherence in previous studies. 7, [26] [27] [28] [29] [30] These studies showed a wide range in study design, study population, and methods to define nonadherence, which complicates pooling of the results. In the only study which included (self-reported) depression and anxiety as candidate predictor for nonadherence, an association was observed between these factors and nonadherence. 31 In addition, we identified active disease as a predictor for subsequent nonadherent behavior. This might imply that active disease precedes nonadherence in time. However, it is conceivable that active disease merely results from nonadherence, and that nonadherent behavior is sustained longer in time, regardless of the emergence of active disease in some patients. Accordingly, current nonadherence was found to be the best independent predictor for future nonadherence with an adjusted odds ratio of 26.91. This infers that nonadherence may be consistent over longer periods of time (i.e., longer than 3 months) in some patients, thus negatively affecting the disease course. However, we also observed that a considerable number of nonadherent patients reported to become adherent after a follow-up of 3 months. Based on these results, we can conclude that adherence behavior in a patient with IBD shows variability over time, at least in our cohort. Therefore, adherence behavior may be amendable (Fig. 1) .
Nonadherence was most frequently observed in patients using rectally administrated medicine, patients on monotherapy, and in patients having multiple administrations per day. It can be speculated that patients on monotherapy have quiescent disease, and that multiple administrations per day complicate full adherence. However, it may also be an indication that the VAS applies more As measured using the EQ-5D domain-anxiety/depression. OR, Odds ratio.
easily to monotherapy. Also, a higher perceived treatment control and an understanding of disease was associated with adherence to medical therapy. Higher adherence has previously been found to be associated with stronger perceptions of necessity of treatment and with fewer concerns about (negative aspects of) treatment among patients with long-term conditions. 32 Also, a feeling of adequate information about the disease, medication, and illness beliefs and the absence of psychological distress have been found to be associated with adherence behavior in patients with IBD. 6, 9 Our findings corroborate the Common Sense Model, in which it is stated that patients' beliefs play an important role in the modification to the disease. 8, 33 Because these consistent findings open new avenues for therapeutic interventions, we recommend to discuss perceptions about the disease and related treatment with all patients with IBD, especially if nonadherence is suspected. Of note, the B-IPQ has only 9 questions. Thus, illness perceptions, including possible barriers for nonadherence, can easily be obtained. Strengths of this study include the longitudinal nature of the study, resulting in repetitive assessments of medication adherence among patients with IBD. This design enabled us, for the first time, to predict future (non)adherence in individual patients and to report on changes in adherence behavior over time. Moreover, this allowed for extensive correction for confounding. Some aspects of our findings warrant comment. First of all, self-report as a method to assess adherence can be regarded a limitation. Patients may overestimate or underestimate their adherence. Nonadherence identification can either be based on biological assays, 34 pharmacy refill data, 1 or questionnaires. 3 In general, questionnaires tend to have a moderate-to-high concordance with other (more invasive) measures of medication adherence. 35 Self-report is an easy and accessible method to assess medication adherence. 12 Using selfreported VAS, nonadherence was observed in 12.1% of patients with CD and 13.3% in patients with UC. Previous studies report nonadherence rates ranging from 7% to 72%, with a majority of studies reporting 30% to 45% of patients to be nonadherent. 5 Variability of measurement techniques and patient populations presumable explain the significant heterogeneity among studies. Because self-report is less objective compared with more invasive methods, the number of true nonadherent patients in our cohort is conceivably larger. Moreover, because patients in our cohort have a median IBD disease duration of more than 10 years, our cohort may represent a group of patients with improved adherence behavior compared with cohorts including predominantly newly diagnosed patients with IBD. We have previously compared the performance of the VAS used, to measure adherence with the validated Modified Morisky Adherence Scale (MMAS-8), [36] [37] [38] and found this tool to be highly accurate for assessing adherence in patients with IBD. 12 The VAS may best be used for oral medications. Regarding biologicals, its use might be limited because adherence rates for weekly or monthly administrations might be less accurate. Of note, a VAS is a crude method for quantifying adherence, but it fails to specify which (number of) pills or other medication is not consumed and for what reason. Second, cohort studies may be prone to selection bias because patients who agree to participate might be more adherent to medical therapy. However, a previously performed nonresponder study of our cohort did not show any significant differences regarding patient and disease characteristics between responders and nonresponders. 10 Third, during follow-up of cohort studies, the amount of missing data among variables generally increases over time. In the COIN-study, many patients were lost to follow-up over time. A comparison between patients who completed the 2-year follow-up questionnaire with those who were lost to follow-up in our study revealed that long-term responders were older and had longer disease duration. 23 Although the percentage of nonadherence among patients did not differ between the first and last assessment, selection bias could not be fully excluded. Mean adherence scores at the first time point were higher in patients who remained in the study throughout the full follow-up period compared with patients who were lost to followup. To minimize possible (selection) bias, all analyses were performed after performing multiple imputation techniques. 22 Despite these limitations, we feel confident that our study reliably reflects long-term adherence behavior among patients with IBD and provides consistent predictive factors during the course of disease.
In conclusion, physicians should be aware that patients younger at diagnosis, patients with a disease flare, with selfreported anxious/depressed feelings, and patients who are currently nonadherent tend to be future nonadherent. Timely identification of patients with IBD at risk of nonadherence and interventions aimed at illness perceptions might improve adherence and prevent a disadvantageous course of disease in the long run.
